Clinical trials are essential in developing new, improved, and more effective treatments and interventions. Without trials, researchers and professionals in the field cannot properly determine whether these new treatments and interventions are safe and effective.
Furthermore, when larger group testing occurs, this allows researchers to identify and ensure that any improvements resulting from the intervention occurs for as many people as possible and are not just occurring in one individual.
Ahead of the J.P. Morgan Health Conference in San Francisco in January 2023, Australian Health Journal met with Clinials CEO & Founder Maree Beare about developing the next generation recruitment platform and digital marketing service for clinical research. Maree talks about the reasons why clinical trials can fail and the importance of bringing participants much more closer to researchers.
With this need, the Clinials platform is geared towards patient centric trials and reducing site burden. The aim is to accelerate lifesaving medicines coming to market by connecting participants and researchers. The platform allows participants to come to researchers with their eligibility in hand among other capabilities.
Supporting CRO’s, sites and sponsors, the Clinials platform uses AI to convert complex trial protocol into plain language and pre-screening questions. This gives researchers the tools to communicate with their participants meaningfully. The plain language text can be used in a variety of situations like researcher led advertising, landing pages and plain language summaries.
-
Improved treatment in advanced-stage Hodgkin lymphoma
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.
-
Family biz succeeds in vaccine approval & distribution
It’s been 10 years since Jenny and Karl Herz started in business. Over the past 10 years they’ve launched Biointelect and Biocelect businesses to help secure approval and distribution for new medicines into Australia.
In this Australian Health Journal interview, Jenny and Karl talk about the journey the husband and wife team took to get the Novavax COVID-19 vaccine (Nuvaxovid) approved and distributed in Australia. The journey didn’t just include talented and diverse skilled staff but also their children working in both organisations.
-
A clinical research career working Sponsor-side, CRO-side to Site-side
In July 2025, Paratus Clinical, a Australian provider of dedicated clinical trial services, announced the appointment of Megan Morrison as its new Chief Executive Officer, at the same time as a significant milestone as the company celebrating over a decade of impact in the clinical research space. Paratus now operates a network of five purpose-built, research-only clinics along Australia’s eastern seaboard.
